Sidebar

  • Magazine
  • Events
  • Videos
  • Gallery
  • Blog
  • Gantry Home

Magazine menu

  • Home
  • News
    • China News
    • Religion
  • lifestyle
  • Tech
  • Financial
  • Military
  • Entertainment
  • Politics
  • Health
  • Sport
  • Environment
  • Opinion
  • Weather
  • Podcasts
  • Video
  • Ads
The Power of Truth®
Friday, May 23, 2025
Friday, May 23, 2025
  • Home
  • News
    • China News
    • Religion
  • lifestyle
  • Tech
  • Financial
  • Military
  • Entertainment
  • Politics
  • Health
  • Sport
  • Environment
  • Opinion
  • Weather
  • Podcasts
  • Video
  • Ads
  1. You are here:  
  2. Health

Radiation plus combination immunotherapy may help preserve bladder in some patients with muscle-invasive bladder cancer

Details
Staff logo
18 February 2025
Health
  • Previous Article A treatment-resistant, severe type of asthma successfully modeled in mice
  • Next Article Newfound circuit better explains how the brain recognizes what is familiar and important
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to new results.
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to new results.

Read more https://www.sciencedaily.com/releases/2025/02/250218145850.htm

  • Previous Article A treatment-resistant, severe type of asthma successfully modeled in mice
  • Next Article Newfound circuit better explains how the brain recognizes what is familiar and important

HUNGRY FOR TRUTH?  FEED THE NEED.

The Power of Truth®
  • Cookies Policy
  • Privacy Policy
  • Terms of Use
  • Contact
Copyright © 2025 Joomla!. All Rights Reserved. Powered by The Power of Truth® - Designed by JoomlArt.com. Bootstrap is a front-end framework of Twitter, Inc. Code licensed under Apache License v2.0. Font Awesome font licensed under SIL OFL 1.1.